[1] |
JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2009[J]. CA A Cancer J Clin, 2009, 59(4): 225-249.
doi: 10.3322/caac.20006
|
[2] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
doi: 10.3322/caac.21442
|
[3] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
doi: 10.3322/caac.v68.6
|
[4] |
PIEPOLI M F, HOES A W, AGEWALL S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)[J]. Eur Heart J, 2016, 37(29): 2315-2381.
doi: 10.1093/eurheartj/ehw106
|
[5] |
HEIDENREICH P A, KAPOOR J R. Radiation induced heart disease: systemic disorders in heart disease[J]. Heart, 2009, 95(3): 252-258.
doi: 10.1136/hrt.2008.149088
|
[6] |
RUTQVIST L E, ROSE C, CAVALLIN-STÅHL E. A systematic overview of radiation therapy effects in breast cancer[J]. Acta Oncol, 2003, 42(5/6): 532-545.
doi: 10.1080/02841860310014444
|
[7] |
HEINZERLING L, OTT P A, HODI F S, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy[J]. J Immunother Cancer, 2016, 4: 50.
doi: 10.1186/s40425-016-0152-y
|
[8] |
HU J R, FLORIDO R, LIPSON E J, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors[J]. Cardiovasc Res, 2019, 115(5): 854-868.
doi: 10.1093/cvr/cvz026
|
[9] |
GAGGIN H K, JANUZZI J L JR. Biomarkers and diagnostics in heart failure[J]. Biochim Biophys Acta, 2013, 1832(12): 2442-2450.
|
[10] |
PARK J J, PARK J B, PARK J H, et al. Global longitudinal strain to predict mortality in patients with acute heart failure[J]. J Am Coll Cardiol, 2018, 71(18): 1947-1957.
doi: 10.1016/j.jacc.2018.02.064
|
[11] |
ZAMORANO J L, LANCELLOTTI P, RODRIGUEZ MUÑOZ D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801.
doi: 10.1093/eurheartj/ehw211
|
[12] |
PATNAIK J L, BYERS T, DIGUISEPPI C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study[J]. Breast Cancer Res, 2011, 13(3): R64.
doi: 10.1186/bcr2901
|
[13] |
GERNAAT S A M, HO P J, RIJNBERG N, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review[J]. Breast Cancer Res Treat, 2017, 164(3): 537-555.
doi: 10.1007/s10549-017-4282-9
|
[14] |
CARDINALE D, COLOMBO A, BACCHIANI G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy[J]. Circulation, 2015, 131(22): 1981-1988.
doi: 10.1161/CIRCULATIONAHA.114.013777
|
[15] |
VON HOFF D D, LAYARD M W, BASA P, et al. Risk factors for doxorubicin-induced congestive heart failure[J]. Ann Intern Med, 1979, 91(5): 710-717.
doi: 10.7326/0003-4819-91-5-710
|
[16] |
FELKER G M, THOMPSON R E, HARE J M, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy[J]. N Engl J Med, 2000, 342(15): 1077-1084.
doi: 10.1056/NEJM200004133421502
|
[17] |
MARTEL S, MAURER C, LAMBERTINI M, et al. Breast cancer treatment-induced cardiotoxicity[J]. Expert Opin Drug Saf, 2017, 16(9): 1021-1038.
doi: 10.1080/14740338.2017.1351541
|